MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E‐mutant colorectal adenocarcinoma

MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E‐mutant colorectal adenocarcinoma

The mitogen‐activated protein kinase (MAPK) pathway plays a central role in colorectal cancers (CRC). In particular, BRAF V600E‐mutant tumors, which represent around 10% of CRCs, are refractory to current therapies. Overexpression and secretion of serine peptidase inhibitor Kazal type 1 (SPINK1) are...

Full description

Bibliographic Details
Main Authors: Kati Räsänen, Kien X. Dang, Harri Mustonen, Tho H. Ho, Susanna Lintula, Hannu Koistinen, Ulf‐Håkan Stenman, Caj Haglund, Jakob Stenman
Format: Article
Language:English
Published: Wiley 2018-02-01
Series:Molecular Oncology
Subjects:
biomarker
BRAF V600E
colorectal cancer
inhibitor
SPINK1
trametinib
Online Access:https://doi.org/10.1002/1878-0261.12160

Similar Items

Similar Items